ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by Cortrophin Gel and brand expansion.
ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast
